<DOC>
	<DOCNO>NCT01206400</DOCNO>
	<brief_summary>To study effect pioglitazone steroidogenic enzyme axis eugonadal men type 2 diabetes mellitus .</brief_summary>
	<brief_title>Effect Pioglitazone Testosterone Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study</brief_title>
	<detailed_description>Several clinical study demonstrate pioglitazone improve insulin sensitivity also decrease plasma androgen concentration ( DHEAS androstenedione ) woman polycystic ovary syndrome ( PCOS ) . However reduction androgen level PCOS whether secondary increase insulin sensitivity due direct effect thiazolidinediones steroidogenesis known.So far , two human study conduct regard effect rosiglitazone ( thiazolidinedione group drug ) testosterone level , one healthy individual another patient type 2 diabetes hypogonadism . But study give equivocal result study population different . Hence plan study effect pioglitazone steroidogenic enzyme axis eugonadal men type 2 diabetes mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>HbA1c level 7.5 % le stable dosage sulphonylurea ( glimepiride 16mg/day ) metformin ( 12g/day ) least six week BMI 2030 kg/m2 . hepatic impairment , coronary artery disease heart failure , renal failure , require insulin therapy HbA1c &gt; 7.5 % , presence macular edema serum albumin &lt; 3gm/dL .</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>eugonadal , testosterone</keyword>
</DOC>